DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: Community Center
Online support, community stories, financial assistance
Amyloid Planet: Perspectives on Amyloidosis and Protein Misfolding Disorders
The most widely used system is the European modification of the original 3-stage Mayo 2004 system which uses Troponin T or I and NT-pro-BNP to divide patients into Stages 1, 2, 3a and 3b. The Mayo 2012 system, which incorporates serum free light chain levels, is another 4-stage variation on this theme.
Finally, there is a British cardiac staging system for transthyretin (ATTR) amyloidosis which was the subject of a prior amyloidosis JC discussion. What all of these publications have in common is the use of NT-pro-BNP as a key cardiac biomarker. What all medical centers don’t have in common is the ability to order this test without having to send out a blood sample.
Related Content
-
people & placesEli Muchtar, MDEli Muchtar is a hematologist at Mayo cl...
-
videos & visualsQ&A with Dispenzieri and Wall – ASG AL Webinar 2.24.24 – 6/8https://www.youtube.com/watch?v=lzrMgtOC...
-
people & placesJ. Emanuel Finet, MDJ. Emanuel Finet is a staff physician in...
-
news & meetingsCombination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis PatientsUpdated research regarding the ANDROMEDA...
-
educationCase Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
-
news & meetingsSan Diego — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 27, 2024When: Saturday, April 27, 2024 AL wi...
-
videos & visualsProthena and the AFFIRM-AL Study: Ansgar Conrad – ASG Webinar 9/13https://www.youtube.com/watch?v=NrEjyVeJ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.